

68. A composition comprising a multispecific antibody according to any one of claims 1-62, a nucleic acid according to any one of claims 63 and 64, an expression vector according to claim 65 or a host cell according to any one of claims 66 and 67.

5 69. The composition according to claim 68, which is a pharmaceutical composition.

70. The pharmaceutical composition according to claim 69, which further comprises a pharmaceutically acceptable carrier.

10 71. The multispecific antibody according to any one of claims 1-62, the nucleic acid according to claim 63 or 64, the expression vector according to claim 65, the host cell according to claim 66 or 67, the composition according to claim 68, or the pharmaceutical composition according to claim 69 or 70 for use as a medicament.

15 72. The multispecific antibody according to any one of claims 1-62, the nucleic acid according to claim 63 or 64, the expression vector according to claim 65, the host cell according to claim 66 or 67, the composition according to claim 68, or the pharmaceutical composition according to claim 69 or 70 for use in the treatment of a disease.

20 73. The multispecific antibody, nucleic acid, expression vector, host cell or composition for use according to claim 72 wherein the disease is an infectious disease.

25 74. The multispecific antibody, nucleic acid, expression vector, host cell or composition for use according to claim 72, wherein the disease is cancer.

30 75. The multispecific antibody, nucleic acid, expression vector, host cell or composition for use according to claim 74, wherein the cancer is selected from the group consisting of melanoma, lung cancer, breast cancer, colon cancer, colorectal cancer renal cancer, cervical cancer and prostate cancer, such as non-small cell lung cancer (NSCLC), colorectal cancer or melanoma.

35 76. Use of a multispecific antibody according to any one of claims 1-62, the nucleic acid according to claim 63 or 64, the expression vector according to claim 65, the host cell according to claim 66 or 67, the composition according to claim 68, or the pharmaceutical composition according to claim 69 or 70 for the manufacture of a medicament for the treatment of cancer.

77. The use according to claim 76, wherein the cancer is selected from the group consisting of melanoma, lung cancer, breast cancer, colon cancer, colorectal cancer, renal cancer, cervical cancer and prostate cancer, such as non-small cell lung cancer (NSCLC), colorectal cancer or melanoma.

5

78. The use according to any one of claims 71-77, wherein the use is in combination with one or more further therapeutic agent, such as a chemotherapeutic agent.

79. A method for producing a bispecific antibody according to claim 62, comprising the steps of

10

- a) providing a first antibody comprising an Fc region, said Fc region comprising a first CH3 region;
- b) providing a second antibody comprising a second Fc region, said Fc region comprising a second CH3 region,

15

wherein the first antibody is a CD40 antibody comprising two first antigen-binding regions according to any of claims 1-62, and the second antibody is a CD137 antibody comprising two second antigen-binding regions according to any of claims 1-62, or vice versa; and wherein the sequences of said first and second CH3 regions are different and are such that the heterodimeric interaction between said first and second CH3 regions is stronger than each of the homodimeric interactions of said first and second CH3 regions;

20

- c) incubating said first antibody together with said second antibody under reducing conditions; and
- d) obtaining said bispecific CD40xCD137 antibody.

25

80. A method for detecting whether cross-linking between CD40- and CD137-expressing cells occurs in a sample obtained from a patient, such as a blood sample, lymph node sample or bone marrow sample, upon administration of a multispecific antibody according to any one of claims 1-62, comprising the steps of:

30

- (i) contacting the sample with a multispecific antibody according to any one of claims 1-62, under conditions that allow for formation of a complex between said multispecific antibody and the CD40- and CD137-expressing cells; and
- (ii) analyzing whether a complex has been formed.

35

81. An anti-idiotypic antibody which binds to the second or first and second antigen-binding region as defined in any of claims 1-62.